These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 23319054)

  • 1. Exon skipping of hepatic APOB pre-mRNA with splice-switching oligonucleotides reduces LDL cholesterol in vivo.
    Disterer P; Al-Shawi R; Ellmerich S; Waddington SN; Owen JS; Simons JP; Khoo B
    Mol Ther; 2013 Mar; 21(3):602-9. PubMed ID: 23319054
    [TBL] [Abstract][Full Text] [Related]  

  • 2. VLDL and IDL apolipoprotein B-100 kinetics in familial hypercholesterolemia due to impaired LDL receptor function or to defective apolipoprotein B-100.
    Zulewski H; Ninnis R; Miserez AR; Baumstark MW; Keller U
    J Lipid Res; 1998 Feb; 39(2):380-7. PubMed ID: 9507998
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antisense oligonucleotide-induced alternative splicing of the APOB mRNA generates a novel isoform of APOB.
    Khoo B; Roca X; Chew SL; Krainer AR
    BMC Mol Biol; 2007 Jan; 8():3. PubMed ID: 17233885
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mipomersen and other therapies for the treatment of severe familial hypercholesterolemia.
    Bell DA; Hooper AJ; Watts GF; Burnett JR
    Vasc Health Risk Manag; 2012; 8():651-9. PubMed ID: 23226021
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The molecular genetic basis and diagnosis of familial hypercholesterolemia in Denmark.
    Jensen HK
    Dan Med Bull; 2002 Nov; 49(4):318-45. PubMed ID: 12553167
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased hepatic secretion of very-low-density-lipoprotein apolipoprotein B-100 in heterozygous familial hypercholesterolaemia: a stable isotope study.
    Cummings MH; Watts GF; Umpleby M; Hennessy TR; Quiney JR; Sönksen PH
    Atherosclerosis; 1995 Feb; 113(1):79-89. PubMed ID: 7755658
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ApoB metabolism in familial hypercholesterolemia. Inconsistencies with the LDL receptor paradigm.
    Fisher WR; Zech LA; Stacpoole PW
    Arterioscler Thromb; 1994 Apr; 14(4):501-10. PubMed ID: 8148348
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of apolipoprotein B metabolism in familial defective apolipoprotein B and heterogeneous familial hypercholesterolemia.
    Gaffney D; Forster L; Caslake MJ; Bedford D; Stewart JP; Stewart G; Wieringa G; Dominiczak M; Miller JP; Packard CJ
    Atherosclerosis; 2002 May; 162(1):33-43. PubMed ID: 11947895
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The affinity of low-density lipoproteins and of very-low-density lipoprotein remnants for the low-density lipoprotein receptor in homozygous familial defective apolipoprotein B-100.
    Gallagher JJ; Myant NB
    Atherosclerosis; 1995 Jun; 115(2):263-72. PubMed ID: 7661885
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
    Sahebkar A; Watts GF
    Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum low density lipoprotein cholesterol level and cholesterol absorption efficiency are influenced by apolipoprotein B and E polymorphism and by the FH-Helsinki mutation of the low density lipoprotein receptor gene in familial hypercholesterolemia.
    Gylling H; Aalto-Setälä K; Kontula K; Miettinen TA
    Arterioscler Thromb; 1991; 11(5):1368-75. PubMed ID: 1911722
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mipomersen, an apolipoprotein B synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: a randomized, double-blind, placebo-controlled trial.
    Thomas GS; Cromwell WC; Ali S; Chin W; Flaim JD; Davidson M
    J Am Coll Cardiol; 2013 Dec; 62(23):2178-84. PubMed ID: 24013058
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A mouse model of human familial hypercholesterolemia: markedly elevated low density lipoprotein cholesterol levels and severe atherosclerosis on a low-fat chow diet.
    Powell-Braxton L; Véniant M; Latvala RD; Hirano KI; Won WB; Ross J; Dybdal N; Zlot CH; Young SG; Davidson NO
    Nat Med; 1998 Aug; 4(8):934-8. PubMed ID: 9701246
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased production of VLDL apoB-100 in subjects with familial hypercholesterolemia carrying the same null LDL receptor gene mutation.
    Tremblay AJ; Lamarche B; Ruel IL; Hogue JC; Bergeron J; Gagné C; Couture P
    J Lipid Res; 2004 May; 45(5):866-72. PubMed ID: 14967814
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo metabolism of ApoB, ApoA-I, and VLDL triglycerides in a form of hypobetalipoproteinemia not linked to the ApoB gene.
    Elias N; Patterson BW; Schonfeld G
    Arterioscler Thromb Vasc Biol; 2000 May; 20(5):1309-15. PubMed ID: 10807747
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lipoprotein Lp(a) in homozygous familial hypercholesterolemia: density profile, particle heterogeneity and apolipoprotein(a) phenotype.
    Guo HC; Chapman MJ; Bruckert E; Farriaux JP; De Gennes JL
    Atherosclerosis; 1991 Jan; 86(1):69-83. PubMed ID: 1829609
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of the low density lipoprotein receptor-binding site in apolipoprotein B100 and the modulation of its binding activity by the carboxyl terminus in familial defective apo-B100.
    Boren J; Lee I; Zhu W; Arnold K; Taylor S; Innerarity TL
    J Clin Invest; 1998 Mar; 101(5):1084-93. PubMed ID: 9486979
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Shifting the LDL-receptor paradigm in familial hypercholesterolemia: novel insights from recent kinetic studies of apolipoprotein B-100 metabolism.
    Barrett PH; Watts GF
    Atheroscler Suppl; 2002 Mar; 2(3):1-4. PubMed ID: 11923121
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gene transfer of cytidine deaminase apoBEC-1 lowers lipoprotein(a) in transgenic mice and induces apolipoprotein B editing in rabbits.
    Hughes SD; Rouy D; Navaratnam N; Scott J; Rubin EM
    Hum Gene Ther; 1996 Jan; 7(1):39-49. PubMed ID: 8825867
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emerging LDL therapies: Mipomersen-antisense oligonucleotide therapy in the management of hypercholesterolemia.
    Toth PP
    J Clin Lipidol; 2013; 7(3 Suppl):S6-10. PubMed ID: 23642326
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.